Keywords: actelion, promising, biotech/pharma, firm, switzerland, biotech/emerging, pharmaceuticalcompany
Actelion: "promising" biotech/pharma firm
Article | 05 June 2000
Switzerland's Actelion is a promising biotech/emerging pharmaceuticalcompany, with two cardiovascular drugs in Phase III, a major collaboration with Genentech ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
